CoChat
Sign Up
Cited by 197Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Treatment

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., Ehler, E.·2014·European Journal of Pain
DOI 10.1002/j.1532-2149.2013.00445.x
Open this paper in CoChat — free account

Abstract

Background: Peripheral neuropathic pain (PNP) associated with allodynia poses a significant clinical challenge. The efficacy of Δ 9‐tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, was investigated in this 15‐week randomized, double‐blind, placebo‐controlled parallel group study. Methods: In total, 303 patients with PNP associated with allodynia were screened; 128 were randomized to THC/CBD spray and 118 to placebo, in addition to their current analgesic therapy. The co‐primary efficacy endpoints were the 30% responder rate in PNP 0–10 numerical rating scale (NRS) score and the mean change from baseline to the end of treatment in this score. Various key secondary measures of pain and functioning were also investigated. Results: At the 30% responder level, there were statistically significant treatment differences in favour of THC/CBD spray in the full analysis (intention‐to‐treat) dataset [p = 0.034; 95% confidence interval (CI): 1.05–3.70]. There was also a reduction in mean PNP 0–10 NRS scores in both treatment groups that was numerically higher in the THC/CBD spray group, but which failed to reach statistical significance. Secondary measures of sleep quality 0–10 NRS score (p = 0.0072) and S ubject G lobal I mpression of C hange (SGIC) (p = 0.023) also demonstrated statistically significant treatment differences in favour of THC/CBD spray treatment. Conclusions: These findings demonstrate that, in a meaningful proportion of otherwise treatment‐resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.

Overview

Integrity signals

Registry

Crossref · 10.1002/j.1532-2149.2013.00445.x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

Sorted by citations

Items 101–197 of 197

Related

See all

Metadata

Authors
Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., & Ehler, E.
Affiliations
  • Gartnavel General Hospital (GB)
  • MAC Clinical Research (United Kingdom) (GB)
  • General University Hospital in Prague (CZ)
  • West Suffolk Hospital (GB)
  • GW Pharmaceuticals (United Kingdom) (GB)
  • Nemocnice Pardubického Kraje (CZ)
Corresponding author
Serpell, M.
ORCID
Venue
European Journal of Pain
Publisher
Wiley
Published
2014-01-13
Volume
18
Issue
7
Pages
999-1012
ISSN
  • 1090-3801 (ISSN-L)
  • 1532-2149
DOI
10.1002/j.1532-2149.2013.00445.x
OpenAlex
W2112026566
Cited by
197
References
41
Citations by year
2026: 8 · 2025: 14 · 2024: 15 · 2023: 12 · 2022: 32 · 2021: 24 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 3
FWCI
7.78
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • European Journal of Pain (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
peripheral neuropathic pain, allodynia, oromucosal spray, cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, sleep quality, treatment-resistant pain, tolerability
MeSH terms
Adult, Aged, Aged, 80 and over, Analgesics, Cannabidiol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Pain Measurement, Peripheral Nervous System Diseases, Dronabinol, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review